 CAMBRIDGE, Mass. OSAKA, Japan--BUSINESS WIRE--Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda today announced that the U.S. Food and Drug Administration FDA granted Breakthrough Therapy Designation BTD to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness EDS in patients with narcolepsy type 1 NT1,2 a chronic ne 